Sample exhibits outstanding inhibitory activity against Streptococcus pneumoniae and Streptococcus agalactiae.

This exceptional fraction demonstrates proven efficacy against Streptococcus pneumoniae and Streptococcus agalactiae. Streptococcus pneumoniae is a pathogenic bacterium responsible for various respiratory infections, while Streptococcus agalactiae can cause infections in newborns and immunocompromised adults. The inhibitory activity against both bacterial species highlights its potential in the development of broad-spectrum therapies.

The inhibitory activity demonstrated by HB4Y1A against these two pathogens is very promising and suggests its potential as a valuable therapeutic option in the development of new drugs. These results support the importance of research in the search for effective compounds against bacterial infections, especially in cases of strains resistant to existing treatments.

Know more about the pathogens